<DOC>
	<DOCNO>NCT00002412</DOCNO>
	<brief_summary>The purpose study see safe effective give MKC-442 plus stavudine ( d4T ) plus didanosine ( ddI ) plus hydroxyurea .</brief_summary>
	<brief_title>A Study MKC-442 Combination With Other Anti-HIV Drugs</brief_title>
	<detailed_description>Patients randomize receive either MKC-442 placebo , along stavudine ( d4T ) , didanosine ( ddI ) , hydroxyurea . Patients treat follow 48 week .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Hydroxyurea</mesh_term>
	<mesh_term>Stavudine</mesh_term>
	<mesh_term>Didanosine</mesh_term>
	<mesh_term>Emivirine</mesh_term>
	<mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Based medical history , medical condition , prior use antiretroviral drug , genotypic analysis predominant strain HIV1 isolate plasma , administration combination two available antiretroviral agent prescription may give MKC442 . Patient must : HIV infection HIV1 RNA great equal 5,000 Roche Amplicor method within 30 day entry . A failed protease inhibitorcontaining regimen . Negative serum beta human chorionic gonadotropin test within 30 day entry . Prior Medication : Allowed : Prior nucleoside reverse transcriptase protease inhibitor . Cytotoxic chemotherapy 30 day prior entry . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Malabsorption severe chronic diarrhea within 30 day prior entry , inability consume adequate oral intake chronic nausea , emesis , abdominal esophageal discomfort . Inadequately controlled seizure disorder . Known intolerance stavudine , didanosine , and/or hydroxyurea . Acute clinically significant medical event within 30 day screen . Any clinical laboratory abnormality great Grade 3 toxicity , exception laboratory value give . Concurrent Treatment : Excluded : Any experimental antiretroviral therapy immunomodulators direct HIV1 , e.g. , IL4 , cyclosporine steroid dose great 40 mg/day . Prior Medication : Excluded : Nonnucleoside reverse transcriptase inhibitor therapy . Prior Treatment : Excluded : Radiation therapy within 30 day entry except local lesion . Transfusion blood blood product within 21 day screen . Cytotoxic therapy within 3 month study entry . Risk Behavior : Excluded : Active substance abuse may interfere compliance protocol evaluation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 1999</verification_date>
	<keyword>Didanosine</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Stavudine</keyword>
	<keyword>Hydroxyurea</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
	<keyword>Anti-HIV Agents</keyword>
	<keyword>Viral Load</keyword>
	<keyword>MKC 442</keyword>
</DOC>